Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes

Novo Nordisk A/S196 enrolled

Overview

This trial is conducted in Europe. The aim of this trial is to establish the dose response relationship on glycaemic control of five dose levels of NNC90-1170.

Study Type

INTERVENTIONAL

Enrollment

196

Conditions

Diabetes Diabetes Mellitus, Type 2

Interventions

placeboDRUG

Once daily injection, under the skin (s.c.) for 12 weeks

liraglutideDRUG

Once daily injection, under the skin (s.c.) for 12 weeks

glimepirideDRUG

Tablets administered orally according to current treatment guidelines. Dose adjusted according to the glycaemic response

Eligibility

Sex: ALLMin age: 30 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects with type 2 diabetes * Duration of diabetes at least 3 months * Both diet treated and patients in therapy with OHA (oral hypoglycemic agents) * Body Mass Index maximum 40 kg/m\^2 * HbA1c based on analysis from central laboratory: Between 7.5-10.0%, both inclusive, for diet treated, or maximum 9.0% for OHA treated Exclusion Criteria: * Liver or renal disease * Cardiac problems * Uncontrolled treated/untreated hypertension * Proliferative retinopathy * Recurrent severe hypoglycaemia as judged by the Investigator * Known or suspected allergy to trial product or related products * Use of any drug (except for OHAs) which in the Investigator's opinion could interfere with the blood glucose level

Locations (29)

Outcomes

Primary Outcomes

HbA1c (glycosylated haemoglobin)

Secondary Outcomes

Fasting plasma glucose

Fructosamine

7-point blood glucose profile

Adverse events

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.